MX2009012762A - Combinaciones novedosas de neramexano para el tratamiento de trastornos neurodegenerativos. - Google Patents

Combinaciones novedosas de neramexano para el tratamiento de trastornos neurodegenerativos.

Info

Publication number
MX2009012762A
MX2009012762A MX2009012762A MX2009012762A MX2009012762A MX 2009012762 A MX2009012762 A MX 2009012762A MX 2009012762 A MX2009012762 A MX 2009012762A MX 2009012762 A MX2009012762 A MX 2009012762A MX 2009012762 A MX2009012762 A MX 2009012762A
Authority
MX
Mexico
Prior art keywords
neramexane
treatment
neurodegenerative disorders
novel combinations
combinations
Prior art date
Application number
MX2009012762A
Other languages
English (en)
Inventor
Christopher Graham Raphael Parsons
Wojciech Danysz
Angelika Hanschmann
Michael Althaus
Alexander Gebauer
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of MX2009012762A publication Critical patent/MX2009012762A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con composiciones que comprenden neramexano y un inhibidor de liberación de glutamato y el uso de dichas combinaciones en el tratamiento de trastornos neurodegenerativos.
MX2009012762A 2007-07-27 2008-07-25 Combinaciones novedosas de neramexano para el tratamiento de trastornos neurodegenerativos. MX2009012762A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US96225907P 2007-07-27 2007-07-27
EP07252976A EP2018854A1 (en) 2007-07-27 2007-07-27 Novel combinations of neramexane for the treatment of neurodegenerative disorders
PCT/EP2008/006162 WO2009015844A1 (en) 2007-07-27 2008-07-25 Novel combinations of neramexane for the treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
MX2009012762A true MX2009012762A (es) 2009-12-15

Family

ID=38599021

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012762A MX2009012762A (es) 2007-07-27 2008-07-25 Combinaciones novedosas de neramexano para el tratamiento de trastornos neurodegenerativos.

Country Status (12)

Country Link
US (1) US20100190751A1 (es)
EP (2) EP2018854A1 (es)
JP (1) JP2010534628A (es)
KR (1) KR20100038120A (es)
CN (1) CN101677972A (es)
AU (1) AU2008281016B2 (es)
BR (1) BRPI0812034A2 (es)
CA (1) CA2683807A1 (es)
MX (1) MX2009012762A (es)
RU (1) RU2432161C1 (es)
WO (1) WO2009015844A1 (es)
ZA (1) ZA200907827B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102106999B (zh) * 2011-02-11 2016-05-11 冯学功 一种治疗中风病后吞咽困难的中药复方制剂及其制备方法
JP5952394B2 (ja) 2011-06-09 2016-07-13 ザ プロクター アンド ギャンブル カンパニー モノアルキルアミン二重界面活性剤系及び可溶性塩を含むパーソナルケア組成物を調製する方法
EA028060B1 (ru) 2011-07-13 2017-10-31 Сайтокинетикс, Инк. Комбинированная терапия бокового амиотрофического склероза
WO2013192610A2 (en) 2012-06-23 2013-12-27 Fox Chase Chemical Diversity Center, Inc. Pro-drugs of riluzole and their method of use for the treatment of amyotrophic lateral sclerosis
RU2538613C2 (ru) * 2012-10-11 2015-01-10 Федеральное государственное бюджетное учреждение науки Институт теоретической и экспериментальной биофизики Российской академии наук Интерлейкин-10, его применение и композиция на его основе для лечения нейродегенеративных процессов в мозге
CN114599397B (zh) * 2019-10-25 2024-05-28 国立大学法人京都大学 Tau蛋白病的预防或治疗剂

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6133299A (en) * 1993-02-25 2000-10-17 Warner-Lambert Company Methods for treating neurodegenerative diseases and disorders using N-(2,6-disubstituted aromatic)-N'-pyridinyl ureas and other anticonvulsant compounds
IL133235A (en) * 1997-06-30 2004-02-19 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane nmda receptor antagonists and pharmaceutical compositions comprising them
WO2004026246A2 (en) * 2002-09-17 2004-04-01 New York University Methods of treating age associated memory impairment (aami), mild cognitive impairment (mci), and dementias with cell cycle inhibitors
EP1874353A1 (en) * 2005-04-05 2008-01-09 Yale University Glutamate modulating agents in the treatment of mental disorders
KR20130136010A (ko) * 2005-04-13 2013-12-11 네우렉슨 인코포레이티드 Ｎｏｓ 저해 활성을 갖는 치환된 인돌 화합물

Also Published As

Publication number Publication date
EP2180888A1 (en) 2010-05-05
JP2010534628A (ja) 2010-11-11
WO2009015844A1 (en) 2009-02-05
KR20100038120A (ko) 2010-04-12
AU2008281016B2 (en) 2011-08-25
US20100190751A1 (en) 2010-07-29
BRPI0812034A2 (pt) 2014-11-18
CA2683807A1 (en) 2009-02-05
ZA200907827B (en) 2010-07-28
RU2010107177A (ru) 2011-09-10
RU2432161C1 (ru) 2011-10-27
EP2018854A1 (en) 2009-01-28
CN101677972A (zh) 2010-03-24
AU2008281016A1 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
PH12015500832A1 (en) Pyrimidine hydroxy amide compounds as protein deacetylase inhibitors and methods of use thereof
ZA201004091B (en) Peptidyl nitriles and uses thereof as dipeptidyl peptidase i inhibitors
MY165620A (en) Cyclopropylamines as lsd1 inhibitors
MY163275A (en) Ibat inhibitors for the treatment of liver diseases
PH12014500053A1 (en) Proteasome inhibitors
GB0515353D0 (en) Food
MX2010007490A (es) Preparacion de derivados de sulfamida.
MY160456A (en) Benzodiazepine bromodomain inhibitor
MX2011011950A (es) Composiciones de dexmedetomidina sublinguales y metodos de uso de las mismas.
MY149705A (en) Pyridino-pyridinone derivatives, preparation therof, and therapeutic use thereof
MY156349A (en) Cleaning compositions and methods
IL205578A0 (en) Aldh-2 inhibitors in the treatment of psychiatric disorders
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MX2009012762A (es) Combinaciones novedosas de neramexano para el tratamiento de trastornos neurodegenerativos.
MX2009004757A (es) Moduladores de regeneracion neuronal.
GB2482817A (en) Novel use
EP2575833A4 (en) THERAPEUTIC AMOUNTS AND USES THEREOF
CA2843611C (en) Compositions and methods for reducing the incidence of equine digestive disorders
MY157533A (en) Effervescent compositions
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
EP2356991A4 (en) USE OF BACTERIA OF THE GENUS TENACIBACULUM TO OBTAIN QUORUM QUENCHING
WO2009123486A8 (en) Use of compounds in the treatment of tau-induced cytotoxicities
MX2011013324A (es) Uso de derivados de oxindol sustituidos para el tratamiento y profilaxis del dolor.
MX2010004814A (es) Metodos para tratar esclerodermia.

Legal Events

Date Code Title Description
HH Correction or change in general
FA Abandonment or withdrawal